A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood

2023-506367-33-00 Protocol 1366-0042 Human pharmacology (Phase I) - Other Ended

Start 16 Jan 2024 · End 14 Mar 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1366-0042

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
16 Jan 2024 → 14 Mar 2024
Decision date (initial)
2023-12-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

VersionLevelCodeTermSystem organ class
21.0 LLT 10053349 Pharmacokinetic study 10022891

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 16 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Boehringer Ingelheim Pharma GmbH & Co. KG
Global Clinical Development & Operations, Birkendorfer Strasse 65, 88397, Biberach An Der Riss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-01-16 2024-03-14 2024-01-18 2024-01-22

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-29 Germany Acceptable
2023-12-04
2023-12-07
2 SUBSTANTIAL MODIFICATION SM-1 2024-02-15 Germany Acceptable
2024-03-11
2024-03-11